na 931 vs retatrutide Biomed Industries presents Phase 2 results for NA-931, a new obesity treatment. | Biomed Industries Inc posted on the topic Incretin-Based Multi-Agonist Therapies for Type

Despite the known increase in obesity and suspected link to IBD, the use of medications to treat obesity in this population remains very low

#BIO2026 #LatinAmerica #HealthcareInnovation Bio-Manguinhos /Fiocruz, a leading public health and biomedical research institution in Brazil, and Thermo Fisher Scientific have signed a Memorandum of Understanding to advance health innovation and explore opportunities for collaboration in biomedical research, diagnostics, vaccines and bioproduction

Cochrane Database of Systematic Reviews 2(2):CD012277

Studies indicate that 86% of GLP-1 users do not meet daily protein requirements, consuming approximately 40g less protein than needed to preserve muscle mass

Combined with the two fiber sources to support the satiety and appetite suppression many dieters want, and we have a powerhouse supplement